Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition

Neurobiology of Aging

Volumn 34, Issue 11, 2013, Pages 2574-2584

  Stumm, Christoph ^a   Hiebel, Christof ^a   Hanstein, Regina ^a,b   Purrio, Martin ^a   Nagel, Heike ^a   Conrad, Andrea ^a   Lutz, Beat ^a   Behl, Christian ^a   Clement, Angela B ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; APP processing; APP23; CB1; Endocannbinoid system; Learning and memory

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CANNABINOID 1 RECEPTOR;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CORTEX; CANNABINOID 1 RECEPTOR DEFICIENCY; COGNITION; CONTROLLED STUDY; GENE OVEREXPRESSION; HIPPOCAMPUS; INFLAMMATION; LEARNING DISORDER; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN METABOLISM; PROTEIN PROCESSING; SUBICULUM;

ALZHEIMER'S DISEASE; APP PROCESSING; APP23; CB1; ENDOCANNBINOID SYSTEM; LEARNING AND MEMORY;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BODY WEIGHT; BRAIN; CELL LINE, TUMOR; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; MICROGLIA; MUTATION; PEPTIDE FRAGMENTS; RECEPTOR, CANNABINOID, CB1;

EID: 84881542568     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.05.027     Document Type: Article

References (53)

1. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42(Pt 1):631-639.
2. Arriagada P.V., Marzloff K., Hyman B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992, 42:1681-1688.
3. Aso E., Palomer E., Juves S., Maldonado R., Munoz F.J., Ferrer I. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP/PS1 mice. J.Alzheimers Dis. 2012, 30:439-459.
4. Asuni A.A., Perry V.H., O'Connor V. Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease. Biochem. Soc. Trans. 2010, 38:545-551.
5. Benard G., Massa F., Puente N., Lourenco J., Bellocchio L., Soria-Gomez E., Matias I., Delamarre A., Metna-Laurent M., Cannich A., Hebert-Chatelain E., Mulle C., Ortega-Gutierrez S., Martin-Fontecha M., Klugmann M., Guggenhuber S., Lutz B., Gertsch J., Chaouloff F., Lopez-Rodriguez M.L., Grandes P., Rossignol R., Marsicano G. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat. Neurosci. 2012, 15:558-564.
6. Benito C., Nunez E., Tolon R.M., Carrier E.J., Rabano A., Hillard C.J., Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J.Neurosci. 2003, 23:11136-11141.
7. Bisogno T., Di Marzo V. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr. Pharm. Des. 2008, 14:2299-3305.
8. Boncristiano S., Calhoun M.E., Howard V., Bondolfi L., Kaeser S.A., Wiederhold K.H., Staufenbiel M., Jucker M. Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol. Aging 2005, 26:607-613.
9. Brahmachari S., Fung Y.K., Pahan K. Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J.Neurosci. 2006, 26:4930-4939.
10. Buchser W.J., Pardinas J.R., Shi Y., Bixby J.L., Lemmon V.P. 96-Well electroporation method for transfection of mammalian central neurons. Biotechniques 2006, 41:619-624.
11. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature 1998, 395:755-756.
12. Chen X., Zhang J., Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons against beta-amyloid insults. Neuroscience 2011, 178:159-168.
13. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J.Clin. Invest. 2003, 112:423-431.
14. Davis A.A., Fritz J.J., Wess J., Lah J.J., Levey A.I. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology invitro and invivo. J.Neurosci. 2010, 30:4190-4196.
15. Dheen S.T., Kaur C., Ling E.A. Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 2007, 14:1189-1197.
16. Dodd G.T., Mancini G., Lutz B., Luckman S.M. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J.Neurosci. 2010, 30:7369-7376.
17. Duyckaerts C., Colle M.A., Dessi F., Piette F., Hauw J.J. Progression of Alzheimer histopathological changes. Acta Neurol. Belg. 1998, 98:180-185.
18. Esposito G., Scuderi C., Valenza M., Togna G.I., Latina V., De Filippis D., Cipriano M., Carratu M.R., Iuvone T., Steardo L. Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PloS One 2011, 6:e28668.
19. Eubanks L.M., Rogers C.J., Beuscher A.E., Koob G.F., Olson A.J., Dickerson T.J., Janda K.D. Amolecular link between the active component of marijuana and Alzheimer's disease pathology. Mol. Pharm. 2006, 3:773-777.
20. Fakhfouri G., Ahmadiani A., Rahimian R., Grolla A.A., Moradi F., Haeri A. Win55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-gamma pathway. Neuropharmacology 2012, 63:653-666.
21. Giannakopoulos P., Herrmann F.R., Bussiere T., Bouras C., Kovari E., Perl D.P., Morrison J.H., Gold G., Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
22. Gonzalez-Tudela A., Martin-Cano D., Moreno E., Martin-Moreno L., Tejedor C., Garcia-Vidal F.J. Entanglement of two qubits mediated by one-dimensional plasmonic waveguides. Phys. Rev. Lett. 2011, 106:020501.
23. Grathwohl S.A., Kalin R.E., Bolmont T., Prokop S., Winkelmann G., Kaeser S.A., Odenthal J., Radde R., Eldh T., Gandy S., Aguzzi A., Staufenbiel M., Mathews P.M., Wolburg H., Heppner F.L., Jucker M. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat. Neurosci. 2009, 12:1361-1363.
24. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
25. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
26. Iuvone T., Esposito G., De Filippis D., Scuderi C., Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders?. CNS Neurosci. Ther. 2009, 15:65-75.
27. Johnston H., Boutin H., Allan S.M. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem. Soc. Trans. 2011, 39:886-890.
28. Jung K.M., Astarita G., Yasar S., Vasilevko V., Cribbs D.H., Head E., Cotman C.W., Piomelli D. An amyloid beta42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol. Aging 2012, 33:1522-1532.
29. Karl T., Cheng D., Garner B., Arnold J.C. The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert Opin. Ther. Targets 2012, 16:407-420.
30. Kelly P.H., Bondolfi L., Hunziker D., Schlecht H.P., Carver K., Maguire E., Abramowski D., Wiederhold K.H., Sturchler-Pierrat C., Jucker M., Bergmann R., Staufenbiel M., Sommer B. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol. Aging 2003, 24:365-378.
31. Lalonde R., Dumont M., Staufenbiel M., Strazielle C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav. Brain Res. 2005, 157:91-98.
32. Marsicano G., Moosmann B., Hermann H., Lutz B., Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J.Neurochem. 2002, 80:448-456.
33. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgansberger W., Di Marzo V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
34. Martin-Moreno A.M., Brera B., Spuch C., Carro E., Garcia-Garcia L., Delgado M., Pozo M.A., Innamorato N.G., Cuadrado A., Ceballos M.L. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J.Neuroinflammation 2012, 9:8.
35. Martin-Moreno A.M., Reigada D., Ramirez B.G., Mechoulam R., Innamorato N., Cuadrado A., de Ceballos M.L. Cannabidiol and other cannabinoids reduce microglial activation invitro and invivo: relevance to Alzheimer's disease. Mol. Pharmacol. 2011, 79:964-973.
36. Mazzola C., Micale V., Drago F. Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 2003, 477:219-225.
37. Milton N.G. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett. 2002, 332:127-130.
38. Morris R.G., Garrud P., Rawlins J.N., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982, 297:681-683.
39. Mulder J., Zilberter M., Pasquare S.J., Alpar A., Schulte G., Ferreira S.G., Kofalvi A., Martin-Moreno A.M., Keimpema E., Tanila H., Watanabe M., Mackie K., Hortobagyi T., de Ceballos M.L., Harkany T. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 2011, 134(Pt 4):1041-1060.
40. Nagy Z., Esiri M.M., Jobst K.A., Morris J.H., King E.M., McDonald B., Litchfield S., Smith A., Barnetson L., Smith A.D. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 1995, 6:21-31.
41. Persson A., Osman A., Bolouri H., Mallard C., Kuhn H.G. Radixin expression in microglia after cortical stroke lesion. Glia 2013, 61:790-799.
42. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30:e36.
43. Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., Prinzen C., Endres K., Hiemke C., Blessing M., Flamez P., Dequenne A., Godaux E., van Leuven F., Fahrenholz F. Adisintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J.Clin. Invest. 2004, 113:1456-1464.
44. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J.Neurosci. 2005, 25:1904-1913.
45. Schellenberg G.D., Montine T.J. The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol. 2012, 124:305-323.
46. Schmitt U., Hiemke C., Fahrenholz F., Schroeder A. Over-expression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice. Behav. Brain Res. 2006, 175:278-284.
47. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl Acad. Sci. U.S.A. 1997, 94:13287-13292.
48. Teng L., Zhao J., Wang F., Ma L., Pei G. AGPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis. Cell. Res. 2010, 20:138-153.
49. Thathiah A., Spittaels K., Hoffmann M., Staes M., Cohen A., Horre K., Vanbrabant M., Coun F., Baekelandt V., Delacourte A., Fischer D.F., Pollet D., De Strooper B., Merchiers P. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science 2009, 323:946-951.
50. van der Stelt M., Mazzola C., Esposito G., Matias I., Petrosino S., De Filippis D., Micale V., Steardo L., Drago F., Iuvone T., Di Marzo V. Endocannabinoids and beta-amyloid-induced neurotoxicity invivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 2006, 63:1410-1424.
51. Varvel S.A., Lichtman A.H. Evaluation of CB1 receptor knockout mice in the Morris water maze. J.Pharmacol. Exp. Ther. 2002, 301:915-924.
52. Williams M. Progress in Alzheimer's disease drug discovery: an update. Curr. Opin. Investig. Drugs 2009, 10:23-34.
53. Williamson L.L., Sholar P.W., Mistry R.S., Smith S.H., Bilbo S.D. Microglia and memory: modulation by early-life infection. J.Neurosci. 2011, 31:15511-15521.